Search

Your search keyword '"Bousiou, Zoi"' showing total 43 results
Start Over Author "Bousiou, Zoi"
43 results on '"Bousiou, Zoi"'

1. SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial

Author

Papadopoulou, Anastasia, Karavalakis, George, Papadopoulou, Efthymia, Xochelli, Aliki, Bousiou, Zoi, Vogiatzoglou, Anastasios, Papayanni, Penelope-Georgia, Georgakopoulou, Aphrodite, Giannaki, Maria, Stavridou, Fani, Vallianou, Ioanna, Kammenou, Maria, Varsamoudi, Evangelia, Papadimitriou, Vasiliki, Giannaki, Chrysavgi, Sileli, Maria, Stergiouda, Zoi, Stefanou, Garyfallia, Kourlaba, Georgia, Gounelas, George, Triantafyllidou, Maria, Siotou, Eleni, Karaglani, Antonia, Zotou, Eleni, Chatzika, Georgia, Boukla, Anna, Papalexandri, Apostolia, Koutra, Maria-Georgia, Apostolou, Dimitra, Pitsiou, Georgia, Morfesis, Petros, Doumas, Michalis, Karampatakis, Theodoros, Kapravelos, Nikolaos, Bitzani, Militsa, Theodorakopoulou, Maria, Serasli, Eva, Georgolopoulos, Grigorios, Sakellari, Ioanna, Fylaktou, Asimina, Tryfon, Stavros, Anagnostopoulos, Achilles, and Yannaki, Evangelia

Published
2023
Full Text
View/download PDF

2. Open-Label Randomized Controlled Study of Ciprofloxacin vs Rifaximin as Neutropenia Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation

Author

Gavriilaki, Eleni, Mallouri, Despina, Laspa, Evgenia, Papakonstantinou, Anna, Lazaridou, Andriana, Varelas, Christos, Baldoumi, Eirini, Giannakopoulou, Angeliki, Demosthenous, Christos, Vardi, Anna, Bousiou, Zoi, Batsis, Ioannis, Gkioula, Georgia, Anagnostopoulos, Achilles, and Sakellari, Ioanna

Published
2024
Full Text
View/download PDF

3. Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients.

Author

Gavriilaki, Eleni, Demosthenous, Christos, Evangelidis, Paschalis, Bousiou, Zoi, Batsis, Ioannis, Vardi, Anna, Mallouri, Despina, Koravou, Eudoxia-Evaggelia, Spyridis, Nikolaos, Panteliadou, Alkistis, Karavalakis, Georgios, Masmanidou, Marianna, Touloumenidou, Tasoula, Papalexandri, Apostolia, Poziopoulos, Christos, Yannaki, Evangelia, Sakellari, Ioanna, Politou, Marianna, and Papassotiriou, Ioannis

Subjects
PLASMINOGEN activators, CYTOKINE release syndrome, STEM cell transplantation, ENDOTHELIUM diseases, UROKINASE
Abstract

Endothelial injury indices, such as Endothelial Activation and Stress Index (EASIX), modified EASIX (m-EASIX), and simplified EASIX (s-EASIX) scores, have been previously associated with chimeric antigen receptor-T (CAR-T) cell immunotherapy complications. Soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor-15 (GDF-15), and soluble C5b-9 (sC5b-9) have been described as markers of endothelial injury post-hematopoietic stem cell transplantation. In the current study, we examined whether suPAR, GDF-15, and sC5b-9 levels were associated with endothelial injury indices in adult CAR-T cell recipients. The levels of these markers were measured in patients before CAR-T cell infusion and in healthy individuals with immunoenzymatic methods. We studied 45 CAR-T cell recipients and 20 healthy individuals as the control group. SuPAR, GDF-15, and sC5b-9 levels were significantly higher in the patients' group compared to the healthy control group (p < 0.001, in all comparisons). SuPAR levels at baseline were associated with the m-EASIX scores calculated at the same time point (p = 0.020), while suPAR and GDF-15 concentrations were correlated with EASIX scores at day 14 post-infusion (p < 0.001 in both comparisons). Moreover, sC5b-9 levels were correlated with the s-EASIX scores at infusion (p = 0.008) and the EASIX scores at day 14 (p = 0.005). In our study, sC5b9, suPAR, and GDF-15 levels were found to reflect endothelial injury in CAR-T cell recipients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Safety and Efficacy of Extracorporeal Photopheresis for Acute and Chronic Graft-versus-Host Disease.

Author

Gavriilaki, Eleni, Papchianou, Eleni, Karavalakis, Giorgos, Batsis, Ioannis, Panteliadou, Alkistis, Lazaridou, Andriana, Mallouri, Despina, Constantinou, Varnavas, Karvouni, Paraskevi, Evangelidis, Paschalis, Papakonstantinou, Anna, Papalexandri, Apostolia, Kaloyannidis, Panayotis, Spyridis, Nikolaos, Bousiou, Zoi, Vardi, Anna, Yannaki, Evangelia, Sotiropoulos, Damianos, and Sakellari, Ioanna

Subjects
HEMATOPOIETIC stem cell transplantation, GRAFT versus host disease, OVERALL survival, CHRONIC diseases, ACUTE diseases
Abstract

Background/Objectives: Despite novel biological agents, steroid-dependent or -refractory graft-versus-host disease (GvHD) remains a severe complication of allogeneic hematopoietic cell transplantation (allo-HCT). Extracorporeal photopheresis (ECP) is an alternative, non-immunosuppressive treatment for patients with acute (aGvHD) or chronic (cGvHD) GvHD. The aim of this study was to investigate the safety and efficacy of ECP in the treatment of acute and chronic GvHD; Methods: We prospectively studied 112 patients with cGvHD who received one or more previous lines of treatment and 28 patients with steroid-dependent or refractory grade II-IV aGvHD post-alloHSCT. Results: In terms of severe aGvHD, most of the patients (19/28) responded to ECP treatment, while the five-year overall survival (OS) was 34%. After adjustment for several confounder factors, the reduction in immunosuppression (p = 0.026) and number of ECP sessions (p < 0.001) were associated with improved OS. Regarding chronic GvHD, only 19 patients failed to respond to ECP treatment; though significantly lower rates of response were presented in patients with visceral involvement (p = 0.037) and earlier post-transplant GVHD diagnosis (p = 0.001). Over a follow-up period of 45.2 [interquartile range (IQR): 5.6–345.1] months, the 5-year cumulative incidence (CI) of cGvHD-related mortality was 21.2% and was significantly reduced in patients with ECP response (p < 0.001), while the 5-year OS was 65.3%. Conclusions: Our results confirm the safety and efficacy of ECP in patients with GvHD and provide sufficient data for further investigation and the best combination drugs needed such that GvHD will not be the major barrier of allo-HCT in the near future. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. A non-interventional study of microcirculation dynamics in allogeneic hematopoietic cell transplantation survivors compared to controls: evidence of impaired microvascular response regardless of conventional cardiovascular risk factors

Author

Gavriilaki, Eleni, Anyfanti, Panagiota, Sakellari, Ioanna, Batsis, Ioannis, Dolgyras, Panagiotis, Lazaridis, Antonios, Nikolaidou, Barbara, Koletsos, Nikolaos, Gavriilaki, Maria, Zarifis, Ippokratis, Masmanidou, Marianna, Bousiou, Zoi, Vardi, Anna, Douma, Stella, Anagnostopoulos, Achilles, and Gkaliagkousi, Eugenia

Published
2022
Full Text
View/download PDF

6. Alteration of Gut Microbiota Composition and Diversity in Acute and/or Chronic Graft-versus-Host Disease Following Hematopoietic Stem Cell Transplantation: A Prospective Cohort Study

Author

Gavriilaki, Eleni, primary, Christoforidi, Maria, additional, Ouranos, Konstantinos, additional, Minti, Fani, additional, Mallouri, Despina, additional, Varelas, Christos, additional, Lazaridou, Andriana, additional, Baldoumi, Eirini, additional, Panteliadou, Alkistis, additional, Bousiou, Zoi, additional, Batsis, Ioannis, additional, Sakellari, Ioanna, additional, and Gioula, Georgia, additional

Published
2024
Full Text
View/download PDF

8. EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy

Author

Gavriilaki, Eleni, Tzannou, Ifigeneia, Batsis, Ioannis, Tsonis, Ioannis, Liga, Maria, Gkirkas, Konstantinos, Ximeri, Maria, Dolgyras, Panagiotis, Bampali, Vasiliki, Evangelidis, Paschalis, Bousiou, Zoi, Vardi, Anna, Demosthenous, Christos, Stroggyli, Eulampia, Bouzani, Maria, Sagiadinou, Eleftheria, Mallouri, Despina, Tzenou, Tatiana, Sotiropoulos, Damianos, Gigantes, Stavros, Anagnostopoulos, Achilles, Karakasis, Dimitrios, Papadaki, Helen, Tsirigotis, Panagiotis, Spyridonidis, Alexandros, Vassilakopoulos, Theodoros, Angelopoulou, Maria, Sakellari, Ioanna, and Baltadakis, Ioannis

Published
2024
Full Text
View/download PDF

9. Isolated Extramedullary Relapse as a Poor Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia

Author

Sakellari, Ioanna, Gavriilaki, Eleni, Batsis, Ioannis, Mallouri, Despina, Gavriilaki, Maria, Apostolou, Chrysa, Iskas, Michalis, Voutiadou, Georgia, Bouziana, Stella, Bousiou, Zoi, Constantinou, Varnavas, Masmanidou, Marianna, Sotiropoulos, Damianos, Yannaki, Evangelia, Lalayanni, Chrysavgi, Pilavaki, Maya, Chatziioannou, Konstantinos, Papayannopoulos, Sotirios, and Anagnostopoulos, Achilles

Published
2019
Full Text
View/download PDF

10. Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in Adult Allogeneic Hematopoietic Cell Transplantation Recipients

Author

Gavriilaki, Eleni, primary, Bousiou, Zoi, additional, Batsis, Ioannis, additional, Vardi, Anna, additional, Mallouri, Despina, additional, Koravou, Evaggelia-Evdoxia, additional, Konstantinidou, Georgia, additional, Spyridis, Nikolaos, additional, Karavalakis, Georgios, additional, Noli, Foteini, additional, Patriarcheas, Vasileios, additional, Masmanidou, Marianna, additional, Touloumenidou, Tasoula, additional, Papalexandri, Apostolia, additional, Poziopoulos, Christos, additional, Yannaki, Evangelia, additional, Sakellari, Ioanna, additional, Politou, Marianna, additional, and Papassotiriou, Ioannis, additional

Published
2023
Full Text
View/download PDF

11. P1395: PENTAVALENT-SPECIFIC T-CELLS POST HAPLO-IDENTICAL TRANSPLANTATION FOR THE TREATMENT OF OPPORTUNISTIC INFECTIONS

Author

Bousiou, Zoi, primary, Kyriakou, Ioannis, additional, Karavalakis, Georgios, additional, Pantazi, Chrysa, additional, Liga, Maria, additional, Vallianou, Ioanna, additional, Giannaki, Maria, additional, Koukoulias, Kyriakos, additional, Zotou, Elena, additional, Batsis, Ioannis, additional, Vardi, Anna, additional, Papalexandri, Apostolia, additional, Kika, Foteini, additional, Spyridonidis, Alexandros, additional, Sakellari, Ioanna, additional, Papadopoulou, Anastasia, additional, and Yannaki, Evangelia, additional

Published
2023
Full Text
View/download PDF

12. PB2261: DECREASE IN NEUTROPHIL-LYMPHOCYTE RATIO IMPACTS OVERALL SURVIVAL OF ADULT PATIENTS WITH HODGKIN LYMPHOMA AFTER ANTI-PD1 TREATMENT

Author

Varelas, Christos, primary, Gavriilaki, Eleni, additional, Dolgiras, Panagiotis, additional, Iskas, Michail, additional, Lalagianni, Chrysavgi, additional, Antonia, Syrigou, additional, Papathanasiou, Maria, additional, Marvaki, Anastasia, additional, Vadikolia, Chrysanthi, additional, Mallouri, Despina, additional, Batsis, Ioannis, additional, Bousiou, Zoi, additional, Vardi, Anna, additional, Karavalakis, Georgios, additional, Spyridis, Nikolaos, additional, Panteliadou, Alkistis Kyra, additional, Masmanidou, Marianna, additional, Yannaki, Evangelia, additional, Arsos, Georgios, additional, Geroukis, Triantafillos, additional, Stavrogianni, Niki, additional, and Sakellari, Ioanna, additional

Published
2023
Full Text
View/download PDF

13. P1311: LONG-TERM SAFETY AND EFFICACY OF EXTRACORPOREAL PHOTOPHERESIS AS EARLY SECOND-LINE TREATMENT FOR PATIENTS WITH STEROID-DEPENDENT OR REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE.

Author

Gavriilaki, Eleni, primary, Batsis, Ioannis, additional, Papchianou, Eleni, additional, Karavalakis, Georgios, additional, Kyra Panteliadou, Alkistis, additional, Bousiou, Zoi, additional, Mallouri, Despina, additional, Demosthenous, Christos, additional, Soulani, Aikaterini, additional, Bouinta, Asimina, additional, Vardi, Anna, additional, Yannaki, Evangelia, additional, Spyridis, Nikolaos, additional, Sotiropoulos, Damianos, additional, Anagnostopoulos, Achilles, additional, and Sakellari, Ioanna, additional

Published
2023
Full Text
View/download PDF

14. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies

Author

Sakellari, Ioanna, Batsis, Ioannis, Bousiou, Zoi, Mallouri, Despina, Constantinou, Varnavas, Gavriilaki, Eleni, Smias, Christos, Yannaki, Evangelia, Kaloyannidis, Panayotis, Papaioannou, Giorgos, Stavroyianni, Niki, Syrigou, Antonia, Sotiropoulos, Damianos, Fylaktou, Asimina, Tsompanakou, Aliki, Saloum, Riad, and Anagnostopoulos, Achilles

Published
2017
Full Text
View/download PDF

15. Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in Adult Allogeneic Hematopoietic Cell Transplantation Recipients.

Author

Gavriilaki, Eleni, Bousiou, Zoi, Batsis, Ioannis, Vardi, Anna, Mallouri, Despina, Koravou, Evaggelia-Evdoxia, Konstantinidou, Georgia, Spyridis, Nikolaos, Karavalakis, Georgios, Noli, Foteini, Patriarcheas, Vasileios, Masmanidou, Marianna, Touloumenidou, Tasoula, Papalexandri, Apostolia, Poziopoulos, Christos, Yannaki, Evangelia, Sakellari, Ioanna, Politou, Marianna, and Papassotiriou, Ioannis

Subjects
*PLASMINOGEN activators, *HEMATOPOIETIC stem cell transplantation, *HEMATOPOIETIC stem cells, *GRAFT versus host disease
Abstract

Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) and graft-versus-host disease (GvHD) represent life-threatening syndromes after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In both conditions, endothelial dysfunction is a common denominator, and development of relevant biomarkers is of high importance for both diagnosis and prognosis. Despite the fact that soluble urokinase plasminogen activator receptor (suPAR) and growth differentiation factor-15 (GDF-15) have been determined as endothelial injury indices in various clinical settings, their role in HSCT-related complications remains unexplored. In this context, we used immunoenzymatic methods to measure suPAR and GDF-15 levels in HSCT-TMA, acute and/or chronic GVHD, control HSCT recipients, and apparently healthy individuals of similar age and gender. We found considerably greater SuPAR and GDF-15 levels in HSCT-TMA and GVHD patients compared to allo-HSCT and healthy patients. Both GDF-15 and suPAR concentrations were linked to EASIX at day 100 and last follow-up. SuPAR was associated with creatinine and platelets at day 100 and last follow-up, while GDF-15 was associated only with platelets, suggesting that laboratory values do not drive EASIX. SuPAR, but not GDF-15, was related to soluble C5b-9 levels, a sign of increased HSCT-TMA risk. Our study shows for the first time that suPAR and GDF-15 indicate endothelial damage in allo-HSCT recipients. Rigorous validation of these biomarkers in many cohorts may provide utility for their usefulness in identifying and stratifying allo-HSCT recipients with endothelial cell impairment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Survival Advantage of Treosulfan Plus Fludarabine Before Allogeneic Hematopoietic Cell Transplantation for Older or Comorbid Patients With Myeloid Malignancies

Author

Sakellari, Ioanna, Gavriilaki, Eleni, Mallouri, Despina, Batsis, Ioannis, Varelas, Christos, Tagara, Sofia, Bousiou, Zoi, Papathanasiou, Maria, Vardi, Anna, Papalexandri, Apostolia, Vadikoliou, Chrysanthi, Athanasiadou, Anastasia, Lalayanni, Chrysavgi, Fylaktou, Asimina, Antoniadis, Konstantinos, and Anagnostopoulos, Achilles

Published
2021
Full Text
View/download PDF

17. Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study

Author

Sakellari, Ioanna, Gavriilaki, Eleni, Chatziioannou, Konstantinos, Papathanasiou, Maria, Mallouri, Despina, Batsis, Ioannis, Bousiou, Zoi, Bouziana, Stella, Constantinou, Varnavas, Douka, Vassiliki, Apostolou, Chrysa, Iskas, Michalis, Lalayanni, Chrysavgi, Athanasiadou, Anastasia, Sotiropoulos, Damianos, Yannaki, Evangelia, Gianouzakos, Vasilis, and Anagnostopoulos, Achilles

Published
2018
Full Text
View/download PDF

18. Endothelial Injury Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: Angiopetin-2 as a Novel Predictor of the Outcome and the Role of Functional Autoantibodies against Angiotensin II Type 1 and Endothelin A Receptor

Author

Vythoulkas, Dionysios, primary, Lazana, Ioanna, additional, Kroupis, Christos, additional, Gavriilaki, Eleni, additional, Konstantellos, Ioannis, additional, Bousiou, Zoi, additional, Chondropoulos, Spiros, additional, Griniezaki, Marianna, additional, Vardi, Anna, additional, Gkirkas, Konstantinos, additional, Karagiannidou, Aggeliki, additional, Batsis, Ioannis, additional, Stamouli, Maria, additional, Sakellari, Ioanna, additional, and Tsirigotis, Panagiotis, additional

Published
2023
Full Text
View/download PDF

19. Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Cellular Therapies: A Real-World Analysis

Author

Gavriilaki, Eleni, primary, Dolgyras, Panagiotis, additional, Dimou-Mpesikli, Sotiria, additional, Poulopoulou, Aikaterini, additional, Demosthenous, Christos, additional, Zachrou, Evangelia, additional, Siasios, Panagiotis, additional, Mallouri, Despina, additional, Vardi, Anna, additional, Bousiou, Zoi, additional, Panteliadou, Alkistis, additional, Masmanidou, Marianna, additional, Lalayanni, Chrysavgi, additional, Yannaki, Evangelia, additional, Sotiropoulos, Damianos, additional, Anagnostopoulos, Achilles, additional, Vyzantiadis, Timoleon Achilleas, additional, and Sakellari, Ioanna, additional

Published
2022
Full Text
View/download PDF

20. Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Hematopoietic Cell Transplantation and Cellular Therapies: A Retrospective Monocenter Real-Life Analysis.

Author

Gavriilaki, Eleni, Dolgyras, Panagiotis, Dimou-Mpesikli, Sotiria, Poulopoulou, Aikaterini, Evangelidis, Paschalis, Evangelidis, Nikolaos, Demosthenous, Christos, Zachrou, Evangelia, Siasios, Panagiotis, Mallouri, Despina, Vardi, Anna, Bousiou, Zoi, Panteliadou, Alkistis, Batsis, Ioannis, Masmanidou, Marianna, Lalayanni, Chrysavgi, Yannaki, Evangelia, Sotiropoulos, Damianos, Anagnostopoulos, Achilles, and Vyzantiadis, Timoleon-Achilleas

Subjects
CELLULAR therapy, RETROSPECTIVE studies, IMMUNOSUPPRESSION, RISK assessment, PRE-exposure prophylaxis, MYCOSES, HEMATOPOIETIC stem cells, CELL transplantation, DISEASE risk factors
Abstract

Simple Summary: Invasive fungal infections (IFD) are a significant cause of morbidity and mortality in patients with hematological malignant disorders. The aim of this retrospective study was to investigate the prevalence and outcome of IFD in patients who received cellular therapies. Adult hematopoietic cell transplantation (HCT), chimeric antigen receptor (CAR) T cell, and gene therapy recipients were retrospectively enrolled. We studied 950 patients who received cellular therapies. No CAR T cell and gene therapy patient showed IFD whereas 3/456 autologous HCT recipients who suffered from primary refractory/relapsed lymphomas presented with probable IFD. A total of 11/473 allogeneic HCT recipients developed probable IFD, possible IFD was found in 31/473 and IFD was proven in 10/473. Three patients were reported to have a second episode of IFD. IFDs were associated with poor outcomes in allogeneic HCT recipients. Further studies are needed to improve diagnostics and therapeutics in high-risk populations, such as allogeneic HCT recipients in whom IFD is associated with poor outcomes. (1) Background: Autologous, allogeneic hematopoietic cell transplantation (HCT) and other cellular therapies, including CAR T cell and gene therapy, constitute a cornerstone in the management of various benign and malignant hematological disorders. Invasive fungal infections (IFD) remain a significant cause of morbidity and mortality in HCT recipients. Therefore, we investigated the prevalence and risk factors of IFD following HCT and other cellular therapies in an era of novel antifungal prophylaxis. (2) Methods: In this study, we retrospectively enrolled adult HCT recipients who were treated at our JACIE-accredited center according to standard operating procedures over the last decade (2013–2022). (3) Results: 950 patients who received cellular therapies were studied. None of the 19 CAR T cell and neither of the two gene therapy recipients developed IFD whereas 3/456 autologous HCT recipients who suffered from primary refractory/relapsed lymphomas presented with probable IFD. Overall, 11 patients who received allogeneic HCT experienced probable IFD, possible IFD was found in 31/473, and IFD was proven in 10/473. A second IFD episode was present in three patients. Four-year OS was significantly lower in proven compared to probable IFD (p = 0.041) and was independently associated with HCT-CI (p = 0.040) and chronic GVHD (p = 0.045). (4) Conclusions: In this real-world cohort, the prevalence of proven and probable IFD in an era of novel antifungal prophylaxis was found to be relatively low. However, IFDs were associated with poor outcomes for patients who received allogeneic HCT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. A non-interventional study of microcirculation dynamics in allogeneic hematopoietic cell transplantation survivors compared to controls: evidence of impaired microvascular response regardless of conventional cardiovascular risk factors

Author

Gavriilaki, Eleni, primary, Anyfanti, Panagiota, additional, Sakellari, Ioanna, additional, Batsis, Ioannis, additional, Dolgyras, Panagiotis, additional, Lazaridis, Antonios, additional, Nikolaidou, Barbara, additional, Koletsos, Nikolaos, additional, Gavriilaki, Maria, additional, Zarifis, Ippokratis, additional, Masmanidou, Marianna, additional, Bousiou, Zoi, additional, Vardi, Anna, additional, Douma, Stella, additional, Anagnostopoulos, Achilles, additional, and Gkaliagkousi, Eugenia, additional

Published
2021
Full Text
View/download PDF

23. Easix Indices Predict CRS and Overall Survival in Adult CAR-T Cell Recipients

Author

Gavriilaki, Eleni, Tzannou, Ifigeneia, Vardi, Anna, Tsonis, Ioannis, Liga, Maria, Girkas, Konstantinos, Ximeri, Maria, Bousiou, Zoi, Bouzani, Maria, Sagiadinou, Eleutheria, Dolgyras, Panagiotis, Bampali, Vasiliki, Mallouri, Despina, Tzenou, Tatiana, Batsis, Ioannis, Spyridis, Nikolaos, Sotiropoulos, Damianos, Anagnostopoulos, Achilles, Karakasis, Dimitrios, Papadaki, Eleni, Tsirigotis, Panagiotis, Spyridonidis, Alexandros, Angelopoulou, Maria, Sakellari, Ioanna, and Baltadakis, Ioannis

Published
2023
Full Text
View/download PDF

24. Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Leves Are Significantly Associated with Edothelial Injury Indices in Adult Allogenic Hematopoietic Cell Transplantation Recipients

Author

Gavriilaki, Eleni, Bousiou, Zoi, Batsis, Ioannis, Vardi, Anna, Mallouri, Despina, Koravou, Evdoxia, Konstantinidou, Georgia, Spyridis, Nikolaos, Karavalakis, Georgios, Patriarcheas, Vasileios, Masmanidou, Marianna, Touloumenidou, Tasoula, Papalexandri, Apostolia, Poziopoulos, Christos, Yannaki, Evangelia, Sakellari, Ioanna, Politou, Marianna, and Papassotiriou, Ioannis

Published
2023
Full Text
View/download PDF

25. Complement Inhibition with Eculizumab in Adult Transplant-Associated Thrombotic Microangiopathy: Opening the Pandora’s Box

Author

Gavriilaki, Eleni, primary, Sakellari, Ioanna, additional, Bousiou, Zoi, additional, Batsis, Ioannis, additional, Mallouri, Despina, additional, Masmanidou, Marianna, additional, Vardi, Anna, additional, Chatzikonstantinou, Thomas, additional, Koravou, Eudoxia-Evaggelia, additional, Touloumenidou, Tasoula, additional, Papalexandri, Apostolia, additional, Yannaki, Evangelia, additional, and Anagnostopoulos, Achilles, additional

Published
2021
Full Text
View/download PDF

26. Risk Factors and Outcomes of Klebsiella pneumoniae Infection Before and After Allogeneic Hematopoietic Cell Transplantation

Author

Gavriilaki, Eleni, primary, Sakellari, Ioanna, additional, Chatzikonstantinou, Thomas, additional, Mallouri, Despina, additional, Batsis, Ioannis, additional, Katsifa, Eleni, additional, Papadimitriou, Stergios, additional, Panteliadou, Alkistis, additional, Baldoumi, Eirini, additional, Demosthenous, Christos, additional, Bousiou, Zoi, additional, Constantinou, Varnavas, additional, Sotiropoulos, Damianos, additional, and Anagnostopoulos, Achilles, additional

Published
2021
Full Text
View/download PDF

27. Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation

Author

Gavriilaki, Eleni, primary, Sakellari, Ioanna, additional, Anyfanti, Panagiota, additional, Batsis, Ioannis, additional, Vardi, Anna, additional, Bousiou, Zoi, additional, Lazaridis, Antonios, additional, Nikolaidou, Barbara, additional, Zarifis, Ippokratis, additional, Masmanidou, Marianna, additional, Yiannaki, Efthalia, additional, Markala, Dimitra, additional, Anagnostopoulos, Achilles, additional, Douma, Stella, additional, and Gkaliagkousi, Eugenia, additional

Published
2020
Full Text
View/download PDF

28. Endothelial and Complement Activation As Predictors of Survival in Adult Allogeneic Hematopoietic Cell Transplantation

Author

Gavriilaki, Eleni, primary, Sakellari, Ioanna, additional, Chatzikonstantinou, Thomas, additional, Mallouri, Despina, additional, Batsis, Ioannis, additional, Vardi, Anna, additional, Bousiou, Zoi, additional, Koravou, Eudoxia-Evaggelia, additional, Masmanidou, Marianna, additional, Touloumenidou, Tasoula, additional, Papalexandri, Apostolia, additional, Athanasiadou, Anastasia, additional, Yannaki, Evangelia, additional, and Anagnostopoulos, Achilles, additional

Published
2020
Full Text
View/download PDF

29. Allogeneic Hematopoietic Cell Transplantation in Patients With Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Clones: Time for a Change

Author

Gavriilaki, Eleni, primary, Sakellari, Ioanna, additional, Mallouri, Despina, additional, Batsis, Ioannis, additional, Chatziconstantinou, Thomas, additional, Vardi, Anna, additional, Bousiou, Zoi, additional, Masmanidou, Marianna, additional, Douka, Vassiliki, additional, Syrigou, Antonia, additional, Sotiropoulos, Damianos, additional, Constantinou, Varnavas, additional, and Anagnostopoulos, Achilles, additional

Published
2020
Full Text
View/download PDF

30. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis

Author

Tsirigotis, Panagiotis Vassilakopoulos, Theodoros Batsis, Ioannis Bousiou, Zoi Gkirkas, Konstantinos Sakellari, Ioanna and Kaloyannidis, Panayotis Roussou, Paraskevi Pangalis, Gerassimos A. Moschogiannis, Maria Vassilopoulos, George and Repousis, Panagiotis Megalakaki, Aekaterini Michalis, Eurydiki and Kalpadakis, Christina Papadaki, Helen A. Kotsianidis, Ioannis Hatzimichael, Eleftheria Spyridonidis, Alexandros and Anargyrou, Konstantinos Poulakidas, Elias Giannoullia, Panagiota and Apostolidis, Ioannis Stamouli, Maria Konstantopoulos, Konstantinos Pappa, Vassiliki Panayiotidis, Panayiotis and Harhalakis, Nikolaos Anagnostopoulos, Achilles Angelopoulou, Maria

Abstract

The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) after autologous stem cell transplantation (auto-SCT) is poor. Recently, the anti-CD30 monoclonal antibody-drug conjugate, brentuximab vedotin (BV), has shown remarkable activity in the setting of R/R cHL. In the pivotal phase II study, BV produced an overall response rate of 75% and a median progression-free survival of 6.7months. Although these results have been reproduced by large registry studies, the impact of BV on the overall survival (OS) of patients with R/R cHL has not been addressed so far. The aim of this study was to examine the impact of BV on OS in the setting of post auto-SCT R/R cHL. Analysis was performed in a group of patients with R/R cHL after a previous auto-SCT reported in the Greek registry during the last 2 decades. By using a multivariate model and censoring patients at the time of subsequent allo-SCT or treatment with immune checkpoint inhibitors, we showed that treatment with BV in the posttransplant relapse setting has a positive impact on the outcome and results in significant improvement of OS. To our knowledge, this the first published study, addressing the impact of BV on the OS in the setting of posttransplant relapse.

Published
2018

31. Risk Factors and Outcomes of Klebsiella Pneumoniae Infection before and after Allogeneic Hematopoietic Cell Transplantation

Author

Gavriilaki, Eleni, primary, Sakellari, Ioanna, additional, Chatziconstantinou, Thomas, additional, Mallouri, Despina, additional, Batsis, Ioannis, additional, Katsifa, Eleni, additional, Papadimitriou, Stergios, additional, Panteliadou, Alkistis, additional, Baldoumi, Eirini, additional, Demosthenous, Christos, additional, Bousiou, Zoi, additional, Constantinou, Varnavas, additional, Sotiropoulos, Damianos, additional, and Anagnostopoulos, Achilles, additional

Published
2019
Full Text
View/download PDF

32. Easix Is Strongly Associated with Complement Activation and Overall Survival in Adult Allogeneic Hematopoietic Cell Transplantation Recipients

Author

Gavriilaki, Eleni, primary, Sakellari, Ioanna, additional, Chatziconstantinou, Thomas, additional, Mallouri, Despina, additional, Batsis, Ioannis, additional, Vardi, Anna, additional, Bousiou, Zoi, additional, Koravou, Evdoxia, additional, Masmanidou, Marianna, additional, Touloumenidou, Tasoula, additional, Papalexandri, Lila, additional, Athanasiadou, Anastasia, additional, Yannaki, Evangelia, additional, and Anagnostopoulos, Achilles, additional

Published
2019
Full Text
View/download PDF

33. Brentuximab vedotin and anti‐PD1 treatment optimize survival in chemo‐refractory Hodgkin lymphoma patients: Real‐world data

Author

Sakellari, Ioanna, primary, Gavriilaki, Eleni, additional, Iskas, Michail, additional, Bousiou, Zoi, additional, Chatziioannidis, Aristotelis, additional, Batsis, I., additional, Mallouri, Despina, additional, Constantinous, Varnavas, additional, Stavroyianni, Niki, additional, Syrigou, Antonia, additional, Marvaki, Anastasia, additional, Pilavaki, Maria, additional, Papaemmanouel, Styliani, additional, and Anagnostopoulos, Achilles, additional

Published
2019
Full Text
View/download PDF

35. Disease Risk Index Is Independently Associated with Long-Term Outcomes of Allogeneic Transplantation Post Reduced-Intensity Conditioning in Lymphoid Malignancies

Author

Sakellari, Ioanna, primary, Bousiou, Zoi, additional, Lazaridou, Andriana, additional, Gavriilaki, Eleni, additional, Batsis, Ioannis, additional, Mallouri, Despina, additional, Iskas, Michalis, additional, Stavroyianni, Niki, additional, Marvaki, Anastasia, additional, Pilavaki, Magia, additional, Papaemmanouil, Styliani, additional, and Anagnostopoulos, Achilles, additional

Published
2018
Full Text
View/download PDF

36. Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation

Author

Gavriilaki, Eleni, primary, Sakellari, Ioanna, additional, Batsis, Ioannis, additional, Mallouri, Despina, additional, Bousiou, Zoi, additional, Vardi, Anna, additional, Yannaki, Evangelia, additional, Constantinou, Varnavas, additional, Tsompanakou, Aliki, additional, Vadikoliou, Chrysanthi, additional, Kaloyannidis, Panayotis, additional, Bamihas, Gerasimos, additional, and Anagnostopoulos, Achilles, additional

Published
2018
Full Text
View/download PDF

37. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis

Author

Tsirigotis, Panagiotis, primary, Vassilakopoulos, Theodoros, additional, Batsis, Ioannis, additional, Bousiou, Zoi, additional, Gkirkas, Konstantinos, additional, Sakellari, Ioanna, additional, Kaloyannidis, Panayotis, additional, Roussou, Paraskevi, additional, Pangalis, Gerassimos A., additional, Moschogiannis, Maria, additional, Vassilopoulos, George, additional, Repousis, Panagiotis, additional, Megalakaki, Aekaterini, additional, Michalis, Eurydiki, additional, Kalpadakis, Christina, additional, Papadaki, Helen A., additional, Kotsianidis, Ioannis, additional, Hatzimichael, Eleftheria, additional, Spyridonidis, Alexandros, additional, Anargyrou, Konstantinos, additional, Poulakidas, Elias, additional, Giannoullia, Panagiota, additional, Apostolidis, Ioannis, additional, Stamouli, Maria, additional, Konstantopoulos, Konstantinos, additional, Pappa, Vassiliki, additional, Panayiotidis, Panayiotis, additional, Harhalakis, Nikolaos, additional, Anagnostopoulos, Achilles, additional, and Angelopoulou, Maria, additional

Published
2018
Full Text
View/download PDF

38. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

Author

Angelopoulou, Maria K., primary, Vassilakopoulos, Theodoros P., additional, Batsis, Ioannis, additional, Sakellari, Ioanna, additional, Gkirkas, Konstantinos, additional, Pappa, Vasiliki, additional, Giannoulia, Panagiota, additional, Apostolidis, Ioannis, additional, Apostolopoulos, Christos, additional, Roussou, Paraskevi, additional, Panayiotidis, Panayiotis, additional, Dimou, Maria, additional, Kyrtsonis, Marie-Christine, additional, Palassopoulou, Maria, additional, Vassilopoulos, Georgios, additional, Moschogiannis, Maria, additional, Kalpadakis, Christina, additional, Margaritis, Dimitrios, additional, Spyridonidis, Alexander, additional, Michalis, Eurydiki, additional, Anargyrou, Konstantinos, additional, Repousis, Panagiotis, additional, Hatzimichael, Eleutheria, additional, Bousiou, Zoi, additional, Poulakidas, Elias, additional, Grentzelias, Dimitrios, additional, Harhalakis, Nikolaos, additional, Pangalis, Gerassimos A., additional, Anagnostopoulos, Achilles, additional, and Tsirigotis, Panagiotis, additional

Published
2017
Full Text
View/download PDF

40. Two-Year Surveillance Study of Nosocomial Infections in Patients with Hematological Malignancies: Risk Factors for Antimicrobial Resistance and Their Impact in Mortality

Author

Bousiou, Zoi, primary, Syrigou, Antonia, additional, Lalayianni, Chrysavgi, additional, Smias, Christos, additional, Sakellari, Ioanna, additional, Tsirou, Kyriaki, additional, Leontopoulos, Konstantinos, additional, Kalaitzidou, Vasiliki, additional, Tsorlini, Eleni, additional, Anagnostopoulos, Achilles, additional, and Sotiropoulos, Damianos, additional

Published
2016
Full Text
View/download PDF

41. Long-Term Outcomes of Total Body Irradiation Plus Cyclophosphamide Versus Busulfan Plus Cyclophosphamide As Conditioning Regimen for Acute Lymphoblastic Leukemia: A Comparative Study

Author

Sakellari, Ioanna, Gavriilaki, Eleni, Chatziioannou, Konstantinos, Papathanasiou, Maria, Mallouri, Despina, Batsis, Ioannis, Bousiou, Zoi, Bouziana, Stella, Constantinou, Varnavas, Douka, Vassiliki, Apostolou, Chrysa, Marvaki, Anastasia, Kaliou, Maria, Iskas, Michalis, Sotiropoulos, Damianos, Yannaki, Evangelia, Smias, Christos, Gianouzakos, Vasilis, and Anagnostopoulos, Achilles

Published
2017
Full Text
View/download PDF

42. Risk Factors and Outcomes of Klebsiella PneumoniaeInfection before and after Allogeneic Hematopoietic Cell Transplantation

Author

Gavriilaki, Eleni, Sakellari, Ioanna, Chatziconstantinou, Thomas, Mallouri, Despina, Batsis, Ioannis, Katsifa, Eleni, Papadimitriou, Stergios, Panteliadou, Alkistis, Baldoumi, Eirini, Demosthenous, Christos, Bousiou, Zoi, Constantinou, Varnavas, Sotiropoulos, Damianos, and Anagnostopoulos, Achilles

Abstract

Introduction:Carbapenemase-producing (KPC) Klebsiella pneumoniae(Kp) infections have emerged as a major healthcare concern worldwide. Although infections are recognized as a major contributor of morbidity and mortality before and after allogeneic hematopoietic cell transplantation (HCT), the burden of Kp infections has not been extensively evaluated. Therefore, we aimed to determine risk factors and outcomes of these infections in HCT recipients.

Published
2019
Full Text
View/download PDF

43. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.

Author

Angelopoulou MK, Vassilakopoulos TP, Batsis I, Sakellari I, Gkirkas K, Pappa V, Giannoulia P, Apostolidis I, Apostolopoulos C, Roussou P, Panayiotidis P, Dimou M, Kyrtsonis MC, Palassopoulou M, Vassilopoulos G, Moschogiannis M, Kalpadakis C, Margaritis D, Spyridonidis A, Michalis E, Anargyrou K, Repousis P, Hatzimichael E, Bousiou Z, Poulakidas E, Grentzelias D, Harhalakis N, Pangalis GA, Anagnostopoulos A, and Tsirigotis P

Subjects
Adult, Brentuximab Vedotin, Female, Hodgkin Disease mortality, Hodgkin Disease pathology, Humans, Immunoconjugates pharmacology, Male, Prognosis, Retrospective Studies, Survival Analysis, Treatment Outcome, Hodgkin Disease drug therapy, Immunoconjugates therapeutic use
Abstract

This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty-seven patients received BV after autologous stem cell transplantation failure, whereas 28 patients were treated with BV without a prior autologous stem cell transplantation, due to advanced age/comorbidities or chemorefractory disease. The median number of prior treatments was 4 and 44% of the patients were refractory to their most recent therapy. The median number of BV cycles was 8 (range, 2-16), and the median time to best response was the fourth cycle. Fifty-seven patients achieved an objective response: twenty-two (23%), a complete response (CR), and 35 patients (37%), a partial, for an overall response rate of 60%. Twelve patients (13%) had stable disease, and the remaining twenty-six (27%) had progressive disease as their best response. At a median follow-up of 11.5 months, median progression-free survival and overall survival were 8 and 26.5 months, respectively. Multivariate analysis showed that chemosensitivity to treatment administered before BV was associated with a significantly increased probability of achieving response to BV (P = .005). Bulky disease (P = .01) and response to BV (P <.001) were significant for progression-free survival, while refractoriness to most recent treatment (P = .04), bulky disease (P = .005), and B-symptoms (P = .001) were unfavorable factors for overall survival. Among the 22 CRs, 5 remain in CR with no further treatment after BV at a median follow-up of 13 months. In conclusion, our data indicate that BV is an effective treatment for R/R HL patients even outside clinical trials. Whether BV can cure a fraction of patients remains to be seen., (© 2017 The Authors Hematological Oncology Published by John Wiley & Sons Ltd.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results